CARE Perspectives - The Impact of Biosimilars in Canada

TheImpactofBiosimilarsinCanada.png
Screen Shot 2017-10-10 at 10.55.30 AM.png

Dr. John Marshall (McMaster University) and Dr. Vipul Jairath (University of Western Ontario) met at the Farncombe Family Digestive Health Research Institute (McMaster University) during the summer of 2017 to discuss a topic of great interest to the CARE Faculty, as well as practicing Canadian gastroenterologists and physicians around the world – biosimilars. 

Biologics have revolutionized the treatment of inflammatory bowel disease (IBD). Many of the biologics used over the years are reaching their patent expiry, and with this loss of exclusivity, biosimilars have been developed. Biosimilars are relatively new to the Canadian landscape, and there is a lot to learn about their impact and how to effectively integrate them into clinical practice. What follows is a review by Dr. Marshall and Dr. Jairath on how existing and future clinical trials are shaping the use of biosimilars in Canada.


Part 1: What have we learned so far?


Part 2: What trials are underway in Crohn's disease?


Part 3: Where is the landscape headed?


Interested in Biosimilars?
Join the discussion at one of CARE's Regional Congresses on Biosimilars this fall!